Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ACT-1014-6470 in Healthy Subjects
NCT04608513Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-1014-6470 in immune-mediated inflammatory diseases (IMIDs) (4 arms), sponsored by Idorsia. Primary endpoint: Safety profile including incidence of treatment-emergent adverse events. Started Nov 2020; status: completed.
02
Drugs
ACT-1014-6470
03
Conditions
immune-mediated inflammatory diseases (IMIDs)
Beyond the preview
Go deeper on NCT04608513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608513.